the effect of tofacitinib on bone mineral density in patients with rheumatoid arthritis

the effect of tofacitinib on bone mineral density in patients with rheumatoid arthritis - the effect of tofa on BMD in RA

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027242

Enrollment

Registered

2017-05-03

Start date

2016-08-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

to determine the effect of tofacitinib on bone

Interventions

tofacitinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: RA patients were eligible if they had active disease during the previous 12 weeks despite prior treatment with methotrexate

Exclusion criteria

Exclusion criteria: patients had received steroids, bisphosphonates, or parathyroid hormone.

Design outcomes

Primary

Measure	Time frame
the comparison of the BMD of the lumbar spine and femoral neck at baseline and 52 weeks after tofacitinib treatment.	—

Secondary

Measure	Time frame
the comparison of the bone marker at baseline and 52 weeks after tofacitinib treatment	—

Countries

Japan

Contacts

Public Contactkensuke kume

hiroshima clinic rheumatology

kumekensuke@live.jp0822320707

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026